Lv1
46 积分 2024-04-01 加入
Intramolecular cyclization of m-homoprenylphenols through oxidative nucleophilic aromatic substitution
1个月前
已完结
Small Molecule Inhibitors Targeting PD-L1, CTLA4, VISTA, TIM-3, and LAG3 for Cancer Immunotherapy (2020-2024)
1个月前
已完结
Chemoselective N‐Acylation of Indoles and Oxazolidinones with Carbonylazoles
1个月前
已完结
Application of covalent modality in proximity-induced drug pharmacology: Early development, current strategy, and feature directions
1个月前
已完结
Advances in protein kinase drug discovery through targeting gatekeeper mutations
2个月前
已完结
Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update
2个月前
已完结
An update patent review of MDM2-p53 interaction inhibitors (2019–2023)
2个月前
已完结
Discovery of novel thiophene[3,2-d]pyrimidine-based tubulin inhibitors with enhanced antitumor efficacy for combined use with anti-pd-l1 immunotherapy in melanoma
3个月前
已完结
PCSK9 inhibitors: a patent review 2018-2023
3个月前
已完结
Abstract 7575: BPI-460372, a covalent, irreversible TEAD inhibitor in Phase I clinical development
3个月前
已关闭
皖公网安备34019202002308
